



NEWS RELEASE

FOR IMMEDIATE RELEASE

CONTACTS:

Corporate:

Sharon Lewis
XDx, Inc.
415-287-2300

Media:

Sheryl Seapy
Pure Communications
949-608-0841

XDx Appoints Industry Veteran Jay M. Moyes as Chief Financial Officer

BRISBANE, California, May 20, 2008 – XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, announced today that it has appointed Jay M. Moyes, a 30-year veteran of the finance and biotechnology industries, as its chief financial officer.

“Jay is a proven business leader with a blend of financial management achievements and extensive experience in the biotechnology field,” stated Pierre Cassigneul, president and chief executive officer of XDx. “We welcome his accounting, budgeting and forecasting expertise, along with his experience building important business relationships with the financial community. Jay’s business acumen, combined with his appreciation of the importance of technology that improves the patient experience and outcome potential, will help XDx as we continue to develop and grow our business.”

Most recently, Moyes served as vice president of finance and CFO at Myriad Genetics, a publicly traded molecular diagnostics and therapeutic development company. Prior to that, Moyes served as CFO of Genmark, an agricultural biotechnology company, and as a CPA with the international public accounting firm of KPMG. He received his BA in economics from Weber State University and his MBA from the University of Utah.

“I am very excited to be a part of such a dynamic, highly motivated team,” commented Jay Moyes. “XDx is committed to delivering innovative diagnostic and monitoring tools to improve patient care, and I look forward to working with the rest of the executive team to realize the full potential of our molecular diagnostics platform and achieve the company’s strategic vision for the future.”

About XDx

XDx’s mission is to improve patient care by developing molecular diagnostics that translate an individual’s immune status into clinically actionable information. XDx is a molecular diagnostics company that utilizes state-of-the-art genomic technology and sophisticated bioinformatics analyses to understand and measure the immune processes

that underlie specific immune-mediated conditions. Physicians can use this information to help optimize patient treatment and minimize the long-term consequences of immunosuppressive therapies. Building on the discoveries made during the development of AlloMap® molecular expression testing for heart transplant patients, which included the identification of many genes and pathways involved in tissue rejection, XDx is developing a product for use by physicians to better manage lung transplant patients. Beyond the use of AlloMap testing in assessing immune response in solid organ transplantation, XDx scientists are applying similar approaches to potentially create new molecular diagnostic tests for the improved clinical management of immune-mediated inflammatory diseases, such as systemic lupus erythematosus (SLE or lupus), to diagnose and predict clinical flares common in a variety of these diseases.

Cautionary Note About Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: challenges inherent in the process of designing molecular expression tests for transplant monitoring, challenges associated with the incorporation of licensed technology into XDx's development process, developmental challenges posed by differences among various forms of transplant rejection and immune mediated diseases, our ability to increase usage of our tests, the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing test and any future tests we may develop, the risks and uncertainties associated with the regulation of our test, our ability to obtain capital when needed, our history of operating losses, and the results of our clinical studies. These forward-looking statements speak only as of the date hereof. XDx disclaims any obligation to update these forward-looking statements.

###